No data to show
XNAS
ETNB
Market cap1.40bUSD
Jun 13, Last price
10.41USD
1D
-4.18%
1Q
13.58%
IPO
-51.29%
Name
89Bio Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
113.80%
Rev. gr., 5y
%
Revenues
0k
Net income
-367m
L+158.16%
CFO
-368m
L+184.72%
Earnings
Aug 04, 2025
Profile
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop pegozafermin for the treatment of severe hypertriglyceridemia. 89bio, Inc. was incorporated in 2018 and is headquartered in San Francisco, California.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | |
| Income | |||||||
Revenues | |||||||
Cost of revenue | 384,656 | 151,477 | 102,489 | ||||
Unusual Expense (Income) | |||||||
NOPBT | (384,656) | (151,477) | (102,489) | ||||
NOPBT Margin | |||||||
Operating Taxes | (692) | 3,867 | 19 | ||||
Tax Rate | |||||||
NOPAT | (383,964) | (155,344) | (102,508) | ||||
Net income | (367,079) 158.16% | (142,189) 39.37% | (102,026) 13.21% | ||||
Dividends | |||||||
Dividend yield | |||||||
Proceeds from repurchase of equity | 157,930 | 496,833 | 117,831 | ||||
BB yield | -19.29% | -62.49% | -26.59% | ||||
| Debt | |||||||
Debt current | 1,454 | 992 | 168 | ||||
Long-term debt | 2,907 | 28,925 | 20,231 | ||||
Deferred revenue | |||||||
Other long-term liabilities | 40,677 | 3,740 | 501 | ||||
Net debt | (435,594) | (548,953) | (167,761) | ||||
| Cash flow | |||||||
Cash from operating activities | (367,823) | (129,186) | (81,090) | ||||
CAPEX | (15) | (4) | (7) | ||||
Cash from investing activities | (40,864) | (123,019) | (33,943) | ||||
Cash from financing activities | 218,586 | 513,111 | 117,831 | ||||
FCF | (385,767) | (157,228) | (102,813) | ||||
| Balance | |||||||
Cash | 439,955 | 578,870 | 188,160 | ||||
Long term investments | |||||||
Excess cash | 439,955 | 578,870 | 188,160 | ||||
Stockholders' equity | (823,828) | (457,149) | (315,542) | ||||
Invested Capital | 1,268,565 | 1,024,799 | 487,920 | ||||
ROIC | |||||||
ROCE | |||||||
| EV | |||||||
Common stock shares outstanding | 104,715 | 71,173 | 34,806 | ||||
Price | 7.82 -29.99% | 11.17 -12.25% | 12.73 -2.60% | ||||
Market cap | 818,868 3.00% | 795,001 79.42% | 443,085 68.68% | ||||
EV | 383,274 | 246,048 | 275,324 | ||||
EBITDA | (393,797) | (151,427) | (102,424) | ||||
EV/EBITDA | |||||||
Interest | 5,290 | 3,586 | 1,922 | ||||
Interest/NOPBT | |||||||